The Center on Reproductive Health, Law, and Policy at UCLA has launched a "Mifepristone Litigation and Federal Action Tracker." The tracker provides "timely, regularly updated, information on the status of current litigation and new federal administrative actions that could shape regulation of and access to mifepristone." A PDF version is here. The tracker currently includes:
- 7 cases filed to protect or expand current access:
- Three FDA Decisionmaking Cases addressing whether current FDA regulations on mifepristone are overly burdensome and restrictive given mifepristone’s safety and effectiveness
- Two Federal Preemption Cases addressing whether federal law preempts (supersedes) and invalidates additional state restrictions on mifepristone beyond FDA’s regulations
- One State Law Case addressing whether additional state restrictions on mifepristone are invalid under state law
- One Due Process Case seeking to prevent any enforcement of a court decision suspending FDA approval of mifepristone without due process
- 1 case filed to restrict current access
- One FDA Decisionmaking Case challenging FDA’s decisions removing prior restrictions on mifepristone, including the inperson dispensing requirement, and seeking to reimpose those restrictions